New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareEnclomiphene vs Cagrilintide

Enclomiphene vs Cagrilintide

Side-by-side comparison of key properties, dosing, and research.

GLP-1 / Weight Loss Agonists
Enclomiphene
GLP-1 / Weight Loss Agonists
Cagrilintide
Summary
Enclomiphene is the trans-isomer of clomiphene citrate, a selective estrogen receptor modulator (SERM) that stimulates endogenous testosterone production by blocking estrogen negative feedback on the hypothalamus and pituitary. Unlike TRT, it restores testosterone while preserving or increasing sperm production and testicular volume.
Cagrilintide is a long-acting amylin analog developed by Novo Nordisk. Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells. Cagrilintide slows gastric emptying, suppresses glucagon, and reduces appetite via central amylin receptors. In combination with semaglutide (CagriSema), Phase 2 trials achieved approximately 15% body weight reduction. Phase 3 trials (REDEFINE program) are ongoing.
Half-Life
5-7 days (long half-life; accumulates)
~7–10 days
Admin Route
Oral
SubQ
Research
Typical Dose
12.5-25 mg per day
0.16 mg → 0.3 mg → 0.6 mg → 1.2 mg → 2.4 mg
Frequency
Once daily or every other day
Once weekly
Key Benefits
  • Restores testosterone to normal range without exogenous androgen administration
  • Preserves or increases sperm production and fertility
  • Maintains testicular volume (unlike TRT which causes testicular atrophy)
  • LH and FSH levels rise, indicating intact HPG axis function
  • Option for hypogonadal men desiring fertility
  • Oral administration (no injection required)
  • ~15% body weight reduction in combination with semaglutide (CagriSema Phase 2)
  • Synergistic appetite suppression complementing GLP-1 receptor agonists
  • Reduces post-meal glucagon excursions improving glycemic control
  • Slows gastric emptying contributing to prolonged satiety
  • Once-weekly dosing via subcutaneous injection
  • Potential for greater weight loss than semaglutide monotherapy
Side Effects
  • Visual disturbances (rare but class-related SERM effect)
  • Mood changes or irritability
  • Hot flashes
  • Elevated estradiol in some users
  • +2 more
  • Nausea (most common, especially during titration)
  • Vomiting
  • Decreased appetite
  • Diarrhea
  • +2 more
Stacks With